These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 19460684

  • 21. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
    Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F.
    Eur Respir J; 2011 Apr; 37(4):806-12. PubMed ID: 20693248
    [Abstract] [Full Text] [Related]

  • 22. Adherence to treatment in children and adolescent patients with cystic fibrosis.
    Zindani GN, Streetman DD, Streetman DS, Nasr SZ.
    J Adolesc Health; 2006 Jan; 38(1):13-7. PubMed ID: 16387243
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial.
    Mainz JG, Schiller I, Ritschel C, Mentzel HJ, Riethmüller J, Koitschev A, Schneider G, Beck JF, Wiedemann B.
    Auris Nasus Larynx; 2011 Apr; 38(2):220-7. PubMed ID: 21030168
    [Abstract] [Full Text] [Related]

  • 25. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW, Bosso JA.
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Dornase alfa in early cystic fibrosis lung disease.
    Robinson PJ.
    Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
    [Abstract] [Full Text] [Related]

  • 28. [Current therapeutic agents: dornase alfa].
    Baran D, Sternon J.
    Rev Med Brux; 1997 Feb; 18(1):37-40. PubMed ID: 9132917
    [Abstract] [Full Text] [Related]

  • 29. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE.
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [Abstract] [Full Text] [Related]

  • 30. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.
    Rozov T, de Oliveira VZ, Santana MA, Adde FV, Mendes RH, Paschoal IA, Caldeira Reis FJ, Higa LY, Toledo AC, Pahl M, Pulmozyme Study Group.
    Pediatr Pulmonol; 2010 Sep; 45(9):874-82. PubMed ID: 20583292
    [Abstract] [Full Text] [Related]

  • 31. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis.
    Hodson ME, McKenzie S, Harms HK, Koch C, Mastella G, Navarro J, Strandvik B, Investigators of the Epidemiologic Registry of Cystic Fibrosis.
    Pediatr Pulmonol; 2003 Nov; 36(5):427-32. PubMed ID: 14520726
    [Abstract] [Full Text] [Related]

  • 32. Dornase alpha and exhaled NO in cystic fibrosis.
    Grasemann H, Lax H, Treseler JW, Colin AA.
    Pediatr Pulmonol; 2004 Nov; 38(5):379-85. PubMed ID: 15390350
    [Abstract] [Full Text] [Related]

  • 33. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME.
    Respiration; 2001 Nov; 68(2):160-4. PubMed ID: 11287830
    [Abstract] [Full Text] [Related]

  • 34. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.
    McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M.
    J Pediatr; 2008 Dec; 153(6):752-7. PubMed ID: 18760423
    [Abstract] [Full Text] [Related]

  • 35. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS, Chou W, Raimundo K, Trzaskoma B, Konstan MW.
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM, Sorkin EM.
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [Abstract] [Full Text] [Related]

  • 38. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL, Lamb H.
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.